Skip to content

Journal for ImmunoTherapy of Cancer

An interview with JITC's Clinical/Translational Cancer Immunotherapy Section Editor, James L. Gulley, MD, PhD

In this two-minute overview, Dr. Gulley describes JITC’s editorial board, global scope and submission process. Learn how JITC fits into the rapidly expanding field of cancer immunotherapy.

Aims and scope

Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed journal that publishes on all aspects of tumor immunology and cancer immunotherapy, aiming to enrich communication and advance scientific understanding in this rapidly evolving field. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity. 

Read more, explore our article types and sections, and submit your manuscript.


View all articles
View all articles

SITC Member Discount

All SITC members submitting to Journal for ImmunoTherapy of Cancer are eligible for  coverage of the journal’s article-processing charge (APC).

This discount must be requested by contacting prior to submission. Upon receiving a waiver code from this contact, authors must select option #2 on the View Publication Charges page to enter the code.

Society affiliation

Learn more about the Society for Immunotherapy of Cancer’s mission to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy at SITC Cancer Immunotherapy CONNECT.


Pedro Romero, Ludwig Center for Cancer Research

Article series

Immune monitoring technology primers
Reviewed by the members of the SITC Immune Biomarkers Task Force, these brief primers highlight important aspects of both standardized and novel technologies available in clinical trial settings.

SITC Cancer immunotherapy guidelines
Developed by experts in the treatment of specific types of cancer, each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients.​​​​​​​

Latest Tweets


2016 Journal Metrics